1. Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
- Author
-
David L. Friedman, Guy J. Manetti, Lida H. Kimmel, Judy Bergeson, Brian Tang, Matthew Zimmermann, Karen Putnam, Trey Sunderland, John J. Bartko, Robert M. Cohen, Gary Linker, and Nadeem Mirza
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Tau protein ,Enzyme-Linked Immunosorbent Assay ,tau Proteins ,Gastroenterology ,Central nervous system disease ,Cerebrospinal fluid ,Degenerative disease ,Alzheimer Disease ,Internal medicine ,medicine ,Humans ,Medical history ,Aged ,Aged, 80 and over ,Immunoassay ,Amyloid beta-Peptides ,biology ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Peptide Fragments ,Pathophysiology ,Cross-Sectional Studies ,Monoclonal ,biology.protein ,Female ,Alzheimer's disease ,business ,Biomarkers - Abstract
ContextAlzheimer disease (AD) is characterized by pathological results at autopsy of amyloid plaques and tau-associated neurofibrillary tangles, but the clinical diagnosis of AD is determined on the basis of medical history, cognitive symptoms, and exclusionary criteria. The search for antemortem biomarkers is intense and has focused on cerebrospinal fluid (CSF) β-amyloid1-42 and tau proteins.ObjectivesTo compare CSF β-amyloid and tau levels in a new population of AD patients and controls. To perform a meta-analysis of studies of CSF β-amyloid and tau levels in AD patients and controls.DesignCross-sectional study of the comparison of baseline CSF β-amyloid1-42 and tau levels in AD patients and controls. Meta-analysis involved 17 studies of CSF β-amyloid and 34 studies of CSF tau.SettingClinical research unit of the National Institute of Mental Health, Bethesda, Md.PatientsThe Geriatric Psychiatry Branch evaluated AD patients as inpatients at the National Institutes of Health Clinical Center between May 1985 and January 2001. A total of 203 patients participated in this study (131 with AD and 72 controls). None had other serious illnesses, and 31 of 131 AD cases had AD confirmed at autopsy. Meta-analysis provided an additional 3133 AD patients and 1481 controls.Main Outcome MeasuresLevels of CSF β-amyloid1-42 were measured by a sandwich enzyme-linked immunoabsorbent assay with a polyclonal capture antibody and a monoclonal detection antibody. Levels of CSF tau were measured with a standard commercial immunoassay.ResultsLevels of CSF β-amyloid1-42 were significantly lower in the AD patients vs controls (mean [SD], 183 [121] pg/mL vs 491 [245] pg/mL; P
- Published
- 2003